The January 6, 2015 issue of Cell Metabolism offered exciting news regarding the fight against obesity. Mirabegron, an FDA approved drug for treating overactive bladder, appears to be a viable option for combatting obesity as well. The secret is in Mirabegron’s ability to metabolize brown fat, which generates heat by burning energy, which fights obesity. The new research focused on how Mirabegron effected both the white fat and brown fat in rodents and humans. While the white fat in the body stores energy, the brown fat utilizes the energy, leading to weight loss and weight maintenance.
The aforementioned study was small and involved a dozen young, healthy men who had not previously taken Mirabegron. The male participants were administered 200 milligrams of Mirabegron daily, roughly 50 milligrams higher than the optimal dose for patients taking this drug for overactive bladder. Results were encouraging, with all of the men showing an average increase in their resting metabolic rate by about 203 calories per day. The ability of Mirabegron, as an effectual β3-adrenergic receptor, to stimulate human brown adipose tissue led to the participants’ ability to burn more calories. The assumption is that by Mirabegron leading to a higher rate of glucose consumption, weight loss and maintenance may not be the only advantages of Mirabegron. Research and development teams are now exploring whether Mirabegron may also hold the key to the management of type 2 diabetes. The brown fat, or brown adipose tissue, generates β3-adrenergic receptor levels higher than just about every other organ in the human body. The unique ability of this already approved drug makes Mirabegron an API to watch.
Currently approved as the brand name drug Myrbetriq, marketed by Astellas Pharmaceuticals, Mirabegron is approved for the treatment of overactive bladder. In the class of drugs coined beta-3 adrenergic agonists, Mirabegron works by curtailing frequent, uncontrolled and urgent urination by relaxing the bladder muscles. A long-acting tablet is available for patients, which is taken once daily, with or without food. Adverse effects are uncommon, with most side effects reported being minor. A small number of patients currently taking Mirabegron for overactive bladder experience headache, dizziness, dry mouth and stomach pain.
LGM Pharma can assist clients as a supplier/distributor of the Mirabegron, CAS # 223673-61-8 API for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.